AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial.
Saved in:
| Title: | AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial. |
|---|---|
| Authors: | Doffman SR; Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass. Electronic address: sarah.doffman@astrazeneca.com., Dosanjh DPS; Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass; Birmingham Acute Care Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom., Sadiq MW; Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Matsunaga Y; Global Development, Inflammation, R&D, Amgen Inc., Thousand Oaks, Calif., Cooper JD; Biometrics and Statistical Innovation, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass., Edwards G; Biometrics and Statistical Innovation, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass., Asimus S; Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Abuqayyas L; Clinical Pharmacology Modeling and Simulation, Amgen, Cambridge, Mass., Zhou XH; Patient Safety Biopharma, Chief Medical Office, Oncology R&D, AstraZeneca, Gothenburg, Sweden., Scott IC; Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass., Cardner M; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Parnes JR; Early Development, Amgen Inc., Thousand Oaks, Calif., Kovacina K; Bioanalysis, AstraZeneca, San Francisco, Calif., White N; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, Mass., Cushion MG; Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass., Belvisi MG; Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Respiratory Pharmacology, National Heart and Lung Institute, Imperial College London, London, United Kingdom., Saralaya D; Respiratory Medicine, Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom., Brown T; Respiratory Medicine, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom., Beier J; Insaf Respiratory Research Institute, Taunusstein, Germany., Molfino NA; Global Development, Inflammation, R&D, Amgen Inc., Thousand Oaks, Calif. |
| Source: | The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2026 Apr 20. Date of Electronic Publication: 2026 Apr 20. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Mosby Country of Publication: United States NLM ID: 1275002 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6825 (Electronic) Linking ISSN: 00916749 NLM ISO Abbreviation: J Allergy Clin Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
